Learn from the best in healthcare. We present you with real-time developments and actionable strategies. Register to ask your immediate questions and to access our slides.
With the rise in state-based and regional comparative effectiveness research (CER), local CER programs like the New England Comparative Effectiveness Review Public Advisory Council (CEPAC) have become increasingly influential in payer decision making.
The biopharma/device merger and acquisitions space is proving extremely lively in 2014, and an early read on the magnitude of risk is essential for effectively triaging deal flow.
Patient engagement has become a new buzz word in drug development. Nevertheless, much uncertainty still exists among stakeholders on how and when to best engage patients in the product development and approval processes.
Debbie Lucas from Avalere Health will discuss the emerging and complex quality landscape from the perspectives of healthcare stakeholders, including providers, health systems, health plans and others across the industry.